254 related articles for article (PubMed ID: 19528470)
1. An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.
Rausch MP; Hahn T; Ramanathapuram L; Bradley-Dunlop D; Mahadevan D; Mercado-Pimentel ME; Runyan RB; Besselsen DG; Zhang X; Cheung HK; Lee WC; Ling LE; Akporiaye ET
Anticancer Res; 2009 Jun; 29(6):2099-109. PubMed ID: 19528470
[TBL] [Abstract][Full Text] [Related]
2. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
Suzuki E; Kim S; Cheung HK; Corbley MJ; Zhang X; Sun L; Shan F; Singh J; Lee WC; Albelda SM; Ling LE
Cancer Res; 2007 Mar; 67(5):2351-9. PubMed ID: 17332368
[TBL] [Abstract][Full Text] [Related]
3. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.
Park CY; Min KN; Son JY; Park SY; Nam JS; Kim DK; Sheen YY
Cancer Lett; 2014 Aug; 351(1):72-80. PubMed ID: 24887560
[TBL] [Abstract][Full Text] [Related]
4. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
Fu K; Corbley MJ; Sun L; Friedman JE; Shan F; Papadatos JL; Costa D; Lutterodt F; Sweigard H; Bowes S; Choi M; Boriack-Sjodin PA; Arduini RM; Sun D; Newman MN; Zhang X; Mead JN; Chuaqui CE; Cheung HK; Zhang X; Cornebise M; Carter MB; Josiah S; Singh J; Lee WC; Gill A; Ling LE
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):665-71. PubMed ID: 18202322
[TBL] [Abstract][Full Text] [Related]
5. Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5.
Engebretsen KV; Skårdal K; Bjørnstad S; Marstein HS; Skrbic B; Sjaastad I; Christensen G; Bjørnstad JL; Tønnessen T
J Mol Cell Cardiol; 2014 Nov; 76():148-57. PubMed ID: 25169971
[TBL] [Abstract][Full Text] [Related]
6. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.
Garrison K; Hahn T; Lee WC; Ling LE; Weinberg AD; Akporiaye ET
Cancer Immunol Immunother; 2012 Apr; 61(4):511-21. PubMed ID: 21971588
[TBL] [Abstract][Full Text] [Related]
7. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
Park CY; Kim DK; Sheen YY
Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo.
Ge R; Rajeev V; Ray P; Lattime E; Rittling S; Medicherla S; Protter A; Murphy A; Chakravarty J; Dugar S; Schreiner G; Barnard N; Reiss M
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4315-30. PubMed ID: 16857807
[TBL] [Abstract][Full Text] [Related]
9. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Melisi D; Ishiyama S; Sclabas GM; Fleming JB; Xia Q; Tortora G; Abbruzzese JL; Chiao PJ
Mol Cancer Ther; 2008 Apr; 7(4):829-40. PubMed ID: 18413796
[TBL] [Abstract][Full Text] [Related]
10. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis.
Son JY; Park SY; Kim SJ; Lee SJ; Park SA; Kim MJ; Kim SW; Kim DK; Nam JS; Sheen YY
Mol Cancer Ther; 2014 Jul; 13(7):1704-16. PubMed ID: 24817629
[TBL] [Abstract][Full Text] [Related]
11. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Wendt MK; Schiemann WP
Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
[TBL] [Abstract][Full Text] [Related]
13. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.
Kim S; Buchlis G; Fridlender ZG; Sun J; Kapoor V; Cheng G; Haas A; Cheung HK; Zhang X; Corbley M; Kaiser LR; Ling L; Albelda SM
Cancer Res; 2008 Dec; 68(24):10247-56. PubMed ID: 19074893
[TBL] [Abstract][Full Text] [Related]
14. TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.
Bouquet F; Pal A; Pilones KA; Demaria S; Hann B; Akhurst RJ; Babb JS; Lonning SM; DeWyngaert JK; Formenti SC; Barcellos-Hoff MH
Clin Cancer Res; 2011 Nov; 17(21):6754-65. PubMed ID: 22028490
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
[TBL] [Abstract][Full Text] [Related]
16. Tranilast inhibits the growth and metastasis of mammary carcinoma.
Chakrabarti R; Subramaniam V; Abdalla S; Jothy S; Prud'homme GJ
Anticancer Drugs; 2009 Jun; 20(5):334-45. PubMed ID: 19322072
[TBL] [Abstract][Full Text] [Related]
17. TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma.
Liu J; Liao S; Diop-Frimpong B; Chen W; Goel S; Naxerova K; Ancukiewicz M; Boucher Y; Jain RK; Xu L
Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16618-23. PubMed ID: 22996328
[TBL] [Abstract][Full Text] [Related]
18. A Small Dibromotyrosine Derivative Purified From Pseudoceratina Sp. Suppresses TGF-β Responsiveness by Inhibiting TGF-β Type I Receptor Serine/Threonine Kinase Activity.
Chen CL; Kao YC; Yang PH; Sung PJ; Wen ZH; Chen JJ; Huang YB; Chen PY
J Cell Biochem; 2016 Dec; 117(12):2800-2814. PubMed ID: 27153151
[TBL] [Abstract][Full Text] [Related]
19. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host.
Zhang Z; Hu Z; Gupta J; Krimmel JD; Gerseny HM; Berg AF; Robbins JS; Du H; Prabhakar B; Seth P
Cancer Gene Ther; 2012 Sep; 19(9):630-6. PubMed ID: 22744210
[TBL] [Abstract][Full Text] [Related]
20. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.
Park SJ; Choi YS; Lee S; Lee YJ; Hong S; Han S; Kim BC
Cancer Lett; 2016 Oct; 381(2):314-22. PubMed ID: 27543359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
